Oxygen News and Research

RSS

Aurora-A protein blocks proper functioning of tumor-suppressor p73

A protein abundantly found in treatment-resistant cancers holds an important tumor-suppressor out of the cell nucleus, where it would normally detect DNA damage and force defective cells to kill themselves, a team of scientists reports in the current Cancer Cell.

28 Feb 2012

Enrollment complete in Ikaria iNO Pivotal Phase III trial for BPD

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD).

27 Feb 2012

Nicotine can contribute to atherosclerosis

Cigarette smoke has long been considered the main risk factor for heart disease. But new research from Brown University in Providence, R.I., shows that nicotine itself, a component of cigarette smoke, can contribute to the disease process by changing cell structure in a way that promotes migration and invasion of the smooth muscle cells that line blood vessels.

24 Feb 2012

Silent & atypical heart attacks more dangerous & fatal in young women

It is known that chest pain or discomfort is the most common heart attack symptom. In addition, fatigue, nausea, shortness of breath and pain or numbness in the jaw, arms or back can also signal a blocked artery cutting off vital oxygen and nutrients from the heart.

22 Feb 2012

Study reveals how mutation shuts down DJ-1 protein's neuroprotective abilities

Purdue University researchers revealed how a mutation in a protein shuts down a protective function needed to prevent the death of neurons in Parkinson's disease, possibly opening the door to new drug strategies to treat the disorder.

22 Feb 2012

Telomerase reactivation in malignant cells after genomic instability causes cancer progression

Inhibiting telomerase, an enzyme that rescues malignant cells from destruction by extending the protective caps on the ends of chromosomes, kills tumor cells but also triggers resistance pathways that allow cancer to survive and spread, scientists report in the Feb. 17 issue of Cell.

21 Feb 2012

Penn oncologist to discuss role of autophagy in fighting cancer at AAAS annual meeting

Blocking autophagy -- the process of "self-eating" within cells -- is turning out to be a viable way to enhance the effectiveness of a wide variety of cancer treatments.

19 Feb 2012

Sentara implements EXTENSION clinical alerting solution for NICU nurses

EXTENSION, INC. announced today that Sentara Princess Anne Hospital in Virginia Beach, VA has successfully implemented its advanced clinical workflow solutions for nursing staff in the Neonatal Intensive Care Unit.

18 Feb 2012

Scientists discover molecular pathway by which maternally inherited deafness appears to occur

Yale scientists have discovered the molecular pathway by which maternally inherited deafness appears to occur: Mitochondrial DNA mutations trigger a signaling cascade, resulting in programmed cell death.

17 Feb 2012

UK's leading model agencies back 'No Sunbed' campaign

Ahead of London Fashion Week, leading model agencies sign groundbreaking 'No Sunbed' policy agreement as part of Cancer Research UK's R UV UGLY? campaign after warnings on health and appearance

17 Feb 2012

Scientists create first 3-D living tissue model of glioma

Brown University scientists have created the first three-dimensional living tissue model, complete with surrounding blood vessels, to analyze the effectiveness of therapeutics to combat brain tumors. The 3-D model gives medical researchers more and better information than Petri dish tissue cultures.

17 Feb 2012

New preclinical data from Regulus' miR-21 study on kidney fibrosis

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new preclinical data investigating the role of microRNA-21 (miR-21) in the treatment of kidney fibrosis has been published in the journal Science Translational Medicine.

17 Feb 2012

Combination of photodynamic therapy and software can treat internal tumours

Laser light in combination with certain drugs - known as photodynamic therapy - can destroy cancer tumours, but is today used mostly to cure skin cancer. The reason that internal tumours are not treated with the method is that the technology does not exist to check that the precise amount of light is administered. However, software developed by researchers in atomic physics at Lund University in Sweden looks like being able to solve the problem.

16 Feb 2012

Heart attack scars mended using stem cells

Researchers from United States have successfully healed the scars caused by a heart attack using stem cells gathered from the patient's own heart. The amount of scar tissue was halved in the small safety trial reported in the Lancet medical journal. The authors said there was also an “unprecedented” increase in new heart muscle.

15 Feb 2012

Ovarian cancer subtype may be susceptible to 'anti-angiogenic' drugs

Scientists at Dana-Farber Cancer Institute have identified a subtype of ovarian cancer able to build its own blood vessels, suggesting that such tumors might be especially susceptible to "anti-angiogenic" drugs that block blood vessel formation.

15 Feb 2012

Prevention and treatment options are improving long-term outcomes for heart failure

"Despite the increasing number of people affected, the prognosis for patients with heart failure has steadily improved," said Gregg C. Fonarow, M.D, chairman of American Heart Association Hospital Accreditation Science Committee and professor of cardiovascular medicine of the University of California, Los Angeles.

14 Feb 2012

Oxygen deprivation disrupts insulin and glucose regulation in rat pups

Premature infants' immature lungs and frequent dips in blood pressure make them especially vulnerable to a condition called hypoxia in which their tissues don't receive enough oxygen, sometimes leading to permanent brain damage. New animal research suggests that a common practice in caring for these babies might in fact exacerbate this condition, increasing the chances for long-term neurological deficits.

14 Feb 2012

Diffusion opens enrollment for TSC clinical trial for newly diagnosed primary brain cancer

Diffusion Pharmaceuticals LLC announced today that it has opened for enrollment a clinical trial testing the company's lead drug candidate trans sodium crocetinate (TSC) as a first-line treatment for newly diagnosed primary brain cancer, also known as glioblastoma or GBM.

13 Feb 2012

Vytacera Pharma to develop Sulfanegen for treatment of cyanide poisoning

Cyanide poisoning is often fatal and typically affects victims of industrial accidents, terrorist attacks, or structural fires. Based on research conducted at the Center for Drug Design at the University of Minnesota, startup Vytacera Pharma Inc. will develop and market Sulfanegen, a treatment for cyanide poisoning. Sulfanegen could be administered by first responders in the case of a mass casualty emergency, or to victims of smoke inhalation from a house fire.

10 Feb 2012

Center for LAM Research and Clinical Care at BWH to conduct phase I combination drug trial

The Center for LAM Research and Clinical Care at Brigham and Women's Hospital (BWH) has been awarded a $1 million plus, four-year grant from the U.S. Department of Defense Office of the Congressionally Directed Medical Research Programs to fund their work on lymphangioleiomyomatosis.

8 Feb 2012